Quantum
Home > Boards > US Listed > Biotechs >

Neurotrope Inc. (NTRP)

NTRP RSS Feed 		Add NTRP Price Alert      Hide Sticky   Hide Intro
Moderator: XenaLives, runncoach, grich1, Cyosol
Search This Board: 
Last Post: 11/11/2018 10:05:46 PM - Followers: 69 - Board type: Free - Posts Today: 0


 
Description:
Neurotrope Bioscience is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
For more information, visit: http://www.neurotrope.com/
Market Information (as of September 30, 2018):
Symbol: NTRP
Stock Price: $8.81
Market Cap: $69,684,395
Outstanding Shares: 7,909,693
Public Float: 6,260,000
Warrants:
- 147,606 warrants exercisable at $0.32 ($47,233.92)
- 382,887 warrants exercisable at $6.40 ($2,450,476.80)
- 3,751,033 warrants exercisable at $12.80 ($48,013,222.40)
- 819,914 warrants exercisable at $32.00 ($26,237,248.00)
- $76,748,181.12 to be raised in total
Options Outstanding: 1,423,961
Fully Diluted Shares (Outstanding Shares + Warrants + Options Outstanding): 14,435,094
Fully Diluted Market Cap: $127,173,178
Links:
Presentations & press releases: http://www.neurotrope.com/ir/
Institutional ownership: https://fintel.io/so/us/ntrp
Relevant research articles: https://justpaste.it/5kdzs
Patents by Daniel L. Alkon: https://patents.justia.com/inventor/daniel-l-alkon
Phase 2a and compassionate use patient results: https://content.iospress.com/articles/journal-of-alzheimers-disease/jad170161?resultNumber=0&totalResults=3&start=0&q=neurotrope&resultsPageSize=10&rows=10
Phase 2b results: https://www.prnewswire.com/news-releases/neurotropes-bryostatin-improves-cognition-in-patients-with-advanced-alzheimers-disease-based-on-further-analysis-of-phase-2-clinical-trial-data-300578025.html
Roth report: https://www.scribd.com/document/379434551/2018-03-08-NTRP-Roth-Init
Maxim report: https://www.scribd.com/document/379427337/NTRP-initiation
Memantine trial results: https://www.nejm.org/doi/full/10.1056/NEJMoa013128
Bryostatin vs. Memantine vs. Placebo comparison: https://i.imgur.com/579PX0L.jpg
Test comparison: https://i.imgur.com/s61opUd.jpg
Quantum
NTRP
Current Price
Volume:
Bid Ask Day's Range
NTRP Detailed Quote
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NTRP News: Quarterly Report (10-q) 10/30/2018 05:04:21 PM
NTRP News: Additional Proxy Soliciting Materials (definitive) (defa14a) 10/24/2018 04:10:15 PM
NTRP News: Proxy Statement (definitive) (def 14a) 10/24/2018 04:08:04 PM
NTRP News: Neurotrope Presents Updated Phase 2 Data of Bryostatin-1 in Moderate to Severe Alzheimer's Disease at the 11th Edition of CTA... 10/24/2018 08:30:00 AM
NTRP News: Neurotrope to Present at the Ladenburg Thalmann 2018 Healthcare Conference 09/27/2018 08:30:00 AM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#5681  Sticky Note Here's the corporate presentation: http://noble.mediasite.com/mediasite/Play/f9 Cyosol 02/05/18 01:55:24 PM
#710  Sticky Note Why I will be watching but not investing XenaLives 02/14/17 10:51:33 AM
#7255   Looks like Alkon will be back in San runncoach 11/11/18 10:05:46 PM
#7254   Twitter link. Sure some have seen it. runncoach 11/11/18 01:53:56 PM
#7253   Neurotrope has provided the data. Even the runncoach 11/11/18 11:07:52 AM
#7252   Noooo... I said you had cherry picked the XenaLives 11/11/18 10:00:01 AM
#7251   I agree that the AVXL data is cherry runncoach 11/11/18 06:52:25 AM
#7250   Cherry picking, suppressing evidence, or the fallacy of XenaLives 11/10/18 09:56:10 PM
#7249   So since anavex accomplished none of this its runncoach 11/10/18 09:06:35 PM
#7248   And all of that is irrelevant to Anavex.. XenaLives 11/10/18 07:29:51 PM
#7247   Of course scoring metrics are a big issue runncoach 11/10/18 04:11:48 PM
#7246   The metrics you mention are not the issue. XenaLives 11/10/18 03:42:09 PM
#7245   "Again - 2-73 is not a "competitor" to Bryostatin" runncoach 11/10/18 03:29:55 PM
#7244   They must know the protocol and there F1ash 11/10/18 03:01:07 PM
#7243   Well that data was presented in a peer-review runncoach 11/10/18 02:50:45 PM
#7242   Anavex 2-73 trial protocol is not disclosed yet XenaLives 11/10/18 02:46:24 PM
#7241   That's why the company makes it very clear runncoach 11/10/18 02:44:33 PM
#7240   Apples and oranges.. XenaLives 11/10/18 02:44:30 PM
#7239   No proof of any other drugs showing superiority InTheTrenches 11/10/18 02:21:03 PM
#7238   Typing too quickly - XenaLives 11/10/18 01:34:16 PM
#7237   The trial extension isn't just about safety, it's XenaLives 11/10/18 01:22:31 PM
#7232   We didn't have to design a safety trial runncoach 11/10/18 12:12:21 PM
#7231   But not YEARS, right? XenaLives 11/10/18 11:48:25 AM
#7230   Seems pretty clear and straight forward to me... XenaLives 11/10/18 11:46:17 AM
#7229   I will grant you that AVXL are very dia76ca 11/10/18 11:40:09 AM
#7228   "Both companies will have significant data around the Whatsupp 11/10/18 10:41:00 AM
#7227   Long enough for the FDA to approval trial runncoach 11/09/18 09:07:05 PM
#7226   How long did those trials with "actual results" last? XenaLives 11/09/18 08:40:04 PM
#7225   For over a week now there have been runncoach 11/09/18 08:26:15 PM
#7224   Actually I don't think they are in competition. dia76ca 11/09/18 08:05:58 PM
#7223   Actually I don't agree. I don't think the runncoach 11/09/18 07:29:15 PM
#7222   "We have to prove it again." I agree. dia76ca 11/09/18 06:06:26 PM
#7221   I had some bids out there but no N2deep1 11/09/18 05:43:58 PM
#7220   It all depends on who you have faith runncoach 11/09/18 04:29:35 PM
#7219   Here's a chart I made that makes the Cyosol 11/09/18 04:27:43 PM
#7218   I would say that post was 99% BS. Whatsupp 11/09/18 04:26:30 PM
#7217   As far as I can tell there is Whatsupp 11/09/18 04:19:33 PM
#7216   Hearing ringing noises in your head is not dia76ca 11/09/18 04:12:04 PM
#7215   Hey, we beat a record today. Cyosol 11/09/18 04:06:08 PM
#7214   I have to say, everything I read about Battle Ready 11/09/18 04:04:30 PM
#7213   On both this board and the Anavex board dia76ca 11/09/18 04:01:34 PM
#7212   Checkmate! And Runncoach drops the mic... Battle Ready 11/09/18 04:00:55 PM
#7211   Sorry, your analysis of ending the placebo arm Whatsupp 11/09/18 04:00:46 PM
#7210   You assume wrong.. XenaLives 11/09/18 03:50:54 PM
#7209   Anavex are getting 40% of the Australian trial dia76ca 11/09/18 03:44:07 PM
#7208   Sorry...I meant to say why AVXL has no InTheTrenches 11/09/18 03:38:30 PM
#7207   Wow. There are interim analysis in double blinded dia76ca 11/09/18 03:32:46 PM
#7206   I'll take 15 out of 16 in a runncoach 11/09/18 03:28:55 PM
#7205   They have approval for Rett Syndrome in the U.S. XenaLives 11/09/18 03:22:36 PM
#7204   94% of a small sample size.. XenaLives 11/09/18 03:21:27 PM
#7203   If what you say is true, and this InTheTrenches 11/09/18 03:18:45 PM
#7201   Luckily we aren't BP and 94% improved so runncoach 11/09/18 03:09:59 PM
PostSubject
© 2018 InvestorsHub.com, Inc.




Ticker News is disabled